在急性失偿性心力衰竭中以尿为导向的尿液疗法:一个评级评估系统审查和元分析与试验序列分析
Ali Saad Al-Shammari1, Khadeeja Ali Hamzah2, Mahyar Masanabadi3
1College of Medicine, University of Baghdad.
Current problems in cardiology
|January 22, 2026
概括
尿路导尿疗法改善了急性失补性心力衰竭 (ADHF) 患者的短期液体和分泌. 然而,这种方法对死亡率或再入院等长期结果没有显著的影响.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 利尿剂耐药性是急性不补偿性心力衰竭 (ADHF) 的一个重要的临床挑战.
- 尿中的 (UNa) 度是循环利尿剂反应的早期指标.
- 在ADHF中,以UNa导向的利尿治疗的临床效用需要进一步研究.
研究的目的:
- 在住院的ADHF患者中系统地审查和元分析UNa引导的利尿剂定位的疗效和安全性.
- 评估UA指导治疗对利尿症,自然利尿症,血栓塞,功能和临床结果的影响.
主要方法:
- 一个系统的审查和对评估UA指导的尿剂定位在ADHF的研究的元分析.
- 在PubMed,Embase,Scopus和CENTRAL进行了搜索,截至2025年10月1日.
- 随机效应模型用于数据聚合,使用I2和x2统计数据评估异质性. 使用GRADE框架对证据的确定性进行了评分.
主要成果:
- 包括五项研究 (三个RCT,两个观察队列).
- 导疗法显著增加了24小时和48小时的尿液和自然尿液 (P < 0.001).
- 在死亡率,再住院,功能障碍或住院时间方面没有发现显著差异. 安全结果在各组中都相似.
结论:
- 在ADHF患者中,以UNa导向的利尿疗法可增强短期的自然尿和利尿,而不会增加不良事件.
- 目前的证据并未证明对死亡率,再住院或脏结果有重大影响.
- 需要进行更大规模的研究来证实UNa引导的尿剂治疗的长期益处和可行性.
更多相关视频
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
1.6K
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
550
相关概念视频
Heart Failure Drugs: Diuretics
830
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
830
Heart Failure VI: Adjunct Therapies
280
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
280
Sieve Analysis and Grading Curves
935
Sieve analysis is a method used to determine the particle size distribution of aggregate materials. This process involves the following steps:
935
Acute Respiratory Failure-I
924
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
924
Acute Respiratory Failure-II
1.1K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.1K
Acute Respiratory Failure-V
480
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
480
